Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23) By Dr Rose Hughes on Wednesday, October 29, 2025 epo G 2/21 G2/21 obvious to try patents PatKat plausibility Rose Hughes Second medical use +
Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy By Dr Rose Hughes on Tuesday, May 27, 2025 antibody inventions epo event report G 1/24 G 2/21 patents PatKat pharma patents plausibility Rose Hughes upc +
UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 By Annsley Merelle Ward on Friday, May 09, 2025 #IPKat AstraZeneca epc G 2/21 Michael Tappin QC patent litigation plausibility SPC sufficiency Teva UK +
Stretching the cheese: Contradictory evidence for a purported technical effect relied on for inventive step (T 0629/22) By Dr Rose Hughes on Monday, May 13, 2024 epo EPO Boards of Appeal G 2/21 G2/21 inventive step patents PatKat plausibility Rose Hughes +
Petition for review filed in referring decision to G2/21 (T 0116/18) By Dr Rose Hughes on Sunday, January 28, 2024 epo EPO Boards of Appeal G 2/21 G2/21 inventive step patents PatKat plausibility Rose Hughes +
Crystallising the interpretation of G 2/21 (T 1989/19) By Dr Rose Hughes on Thursday, December 21, 2023 epo EPO Boards of Appeal G 2/21 G2/21 inventive step patents PatKat plausibility Rose Hughes +
Clarity on the interpretation of G2/21 from the referring Board (T 0116/18) By Dr Rose Hughes on Monday, November 27, 2023 epo G 2/21 G2/21 inventive step patents PatKat plausibility Rose Hughes +